Evotec SE (Evotec) is a drug discovery alliance and development partnership company. It discovers and develops small molecule drugs spanning various conditions areas such as oncology, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides drug discovery services such as target identification and validation, hit identification, sample management, in vitro pharmacology services, integrated CMC, and proteomics services. The company has long-term discovery alliances with several leading pharmaceutical companies and development partnerships for product candidates in clinical and pre-clinical development stages. The company has operating facilities in Abingdon and Alderley Park, the UK; Gottingen and Munich, Germany; Orth an der Donau, Austria; Branford, Princeton and Watertown, the US; Verona, Italy; and Toulouse and Lyon, France. Evotec is headquartered in Hamburg, Germany.
Headquarters
Germany
Address
Essener Bogen 7, Hamburg, 22419
Website
www.evotec.com
Telephone
49 40 560810
No of Employees
4,354
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EVT (ETR)
Revenue (2021)
$730.8M
12.2%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
-83.6%
(2021 vs 2020)
Market Cap*
$4.4B
Net Profit Margin (2020)
XXX
-85.4%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Technologies: | Drug Discovery | J. DISCOVERY |
| Induced Pluripotent Stem Cells (IPSC) Drug Discovery Platform | Target Identification and Validation | J. MD |
| J. DESIGN | Hit Identification | JP3 |
| XXX | XXX | |
| XXX | XXX | |
| XXX | XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In June, the company entered into a drug discovery collaboration with Janssen Pharmaceutica NV to jointly conduct screens on the identified targets. |
| 2022 | Contracts/Agreements | In May, the company entered into an agreement to acquire 100% stake in Rigenerand, an Italy-based cell technology firm for US$24.7 million. |
| 2022 | Contracts/Agreements | In May, the company and Almirall entered into a multi-target alliance in Medical Dermatology. |
Competitor Comparison
| Key Parameters | Evotec SE | Merck & Co Inc | AstraZeneca Plc | GW Pharmaceuticals Plc | Cobra Biologics Ltd |
|---|---|---|---|---|---|
| Headquarters | Germany | United States of America | United Kingdom | United Kingdom | United Kingdom |
| City | Hamburg | Whitehouse Station | Cambridge | Cambridge | Keele |
| State/Province | - | New Jersey | Cambridgeshire | Cambridgeshire | Staffordshire |
| No. of Employees | 4,354 | 68,000 | 83,100 | - | 140 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Werner Lanthaler, Ph.D. | Chief Executive Officer | Senior Management | 2009 | 54 |
| Enno Spillner | Chief Financial Officer | Senior Management | 2016 | 52 |
| Craig Johnstone, Ph.D. | Chief Operating Officer | Senior Management | 2019 | 52 |
| Cord Dohrmann, Ph.D. | Chief Scientific Officer | Senior Management | 2010 | 58 |
| Dr. Iris Low-Friedrich | Vice Chairman | Executive Board | 2019 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer